



## Intellectual Property Acquisition Opportunity

**Bid Deadline  
July 7, 2023**

Hilco Streambank has been engaged by Oncorus to sell or license the company's intangible asset portfolios, including patents and applications, along with supporting research and development materials.

Oncorus is a preclinical-stage biopharmaceutical company founded in 2016 focused on the development of systemically-administered self-amplifying RNA for cancer. The company is in the process of winding down operations and Hilco Streambank is requesting bids by July 7, 2023.

The Oncorus technology is grouped into three portfolios, each of which can be acquired individually.

# LNP Platform

---


Oncorus' proprietary LNP platform uses lipid nanoparticle technology as a delivery system for various potential genetic cargos.

The company's technology is protected by a pending PCT patent application, which is supported by a detailed pre-filing prior art search and recently received an International Search Report that identified patentable composition of matter. The claims cover proprietary ionizable amines and hydrolysable PEG lipids.

The Oncorus LNP platform is highly valuable as it enables multiple potential RNA cargos.

# RNA Platform

The Oncorus self-amplifying RNA technology involves encapsulating genomes of RNA viruses within a lipid nanoparticle, creating a selectively self-amplifying RNA immunotherapy that is administered systemically. The company's lead product candidate is ONCR-021, which is an IV-administered viral RNA encoding an optimized genome of Coxsackievirus 21A, or CVA21.



The company's technology is protected by 8 issued patents, 66 pending applications in various jurisdictions worldwide, and an assignable license to a third-party ionizable lipid that the company has optimized for use with ONCR-021.

In addition to the patent portfolio, the assets available include multiple components of an investigational new drug application (IND) package that the company was in the process of submitting to the U.S. Food and Drug Administration. The IND evaluates ONCR-021 in multiple indications, including non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer, both as monotherapy and in combination with immune checkpoint inhibitors and other cancer treatments.

# HSV Platform

---

Oncorus' proprietary platform uses a microRNA attenuated herpes simplex virus (HSV) as a delivery system for immunomodulatory payloads to target and kill cancer cells and to attract the immune system.

The company's technology is protected by 31 issued patents and 34 pending applications in various jurisdictions worldwide. One of the pending patent applications is a PCT application that covers ONCR-719, which is the company's product candidate for Glioblastoma.

# Available Assets

- LNP Platform PCT Patent Application and US Provisional Application
- Related NHP data, study plans and reports, lipid search memos and data analyses
- 8 issued patents and 66 pending applications with global coverage relating to the RNA Platform
- Development materials, research data, IND documentation, and other records supporting ONCR-021
- 31 issued patents and 34 pending applications with global coverage relating to the HSV Platform, including coverage of ONCR-719



**Bid Deadline  
July 7, 2023**

Please contact Hilco Streambank directly to learn more about the sale process and to request a non-disclosure agreement for access to a virtual data room containing additional materials.

## Contact Us

Gabe Fried CEO <a href="mailto:gfried@hilcoglobal.com">gfried@hilcoglobal.com</a> 617.458.9355	Karl Maersch SVP <a href="mailto:kmaersch@hilcoglobal.com">kmaersch@hilcoglobal.com</a> 440.468.9130
Richelle Kalnit SVP <a href="mailto:rkalnit@hilcoglobal.com">rkalnit@hilcoglobal.com</a> 212.993.7214	Stella Silverstein Analyst <a href="mailto:ssilverstein@hilcoglobal.com">ssilverstein@hilcoglobal.com</a> 646.651.1953



**Hilco**<sup>TM</sup>

Streambank